[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367626-105":59,"doc-detail-367626-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comparison-of-genetic-mutations-in-bladder-cancers-that-arose-following-radiotherapy-for-prostate-cancer-with-those-in-primary-bladder-cancers","Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers","","Radiotherapy (RT) for prostate cancer increases the risk of secondary bladder cancer, yet the genomic differences between RT-associated tumors and primary bladder cancers remain unclear. Fourteen post-brachytherapy cases were grouped as radiation-associated bladder tumors (RA-BT), and 33 primary cases without pelvic RT formed the BT group. TERT promoter mutations were present in 35.7% vs 63.6% (p = 0.112). Rare mutations appeared more often in RA-BT, with increased C→T substitutions and distinct mutation profiles.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-genetic-mutations-in-bladder-cancers-that-arose-following-radiotherapy-for-prostate-cancer-with-those-in-primary-bladder-cancers/367626/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-genetic-mutations-in-bladder-cancers-that-arose-following-radiotherapy-for-prostate-cancer-with-those-in-primary-bladder-cancers/367626.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were patients grouped in the study?","Question",{"text":112,"@type":113},"Fourteen patients who developed primary bladder cancer after brachytherapy formed the radiation-associated bladder tumor (RA-BT) group. Thirty-three patients with primary bladder cancer without prior pelvic RT were classified as the bladder tumor (BT) group.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the reported frequency of TERT promoter mutations in each group?",{"text":117,"@type":113},"TERT promoter mutations occurred in 35.7% of the RA-BT group and 63.6% of the BT group (p = 0.112).",{"name":119,"@type":110,"acceptedAnswer":120},"Which mutation patterns distinguished RA-BT from BT?",{"text":121,"@type":113},"RA-BT showed more rare bladder cancer mutations (including ADGRB3, CBL, TGM7, and BTK) and significantly more C→T substitutions compared with the BT group.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367626,1790640736,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nComparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers  \nShogo Adomi1, Kazuko Sakai2, Yurie Kura2, Marco A De Velasco2, Saizo Fujimoto1, Shingo Toyoda1, Mamoru Hashimoto1, Mitsuhisa Nishimoto3, Eri Banno4, Yoshitaka Saito4, Koichi Sugimoto1, Yujiro Hayashi5, Takafumi Minami1, Kazuhiro Yoshimura1,  \nHirotsugu Uemura1, Kazuto Nishio2 & Kazutoshi Fujita1􀀍  \nRadiotherapy (RT) for prostate cancer increases the risk of bladder cancer. The genomic landscape of bladder cancer following RT for prostate cancer and its differentiation from bladder cancers that develop without a history of pelvic RT remains unclear. We examined gene mutations in bladder cancers that developed following RT and those that developed without prior RT. Fourteen patients who developed primary bladder cancer following brachytherapy were categorized into radiationassociated bladder tumor (RA-BT) group, whereas 33 patients diagnosed with primary bladder cancer without a history of pelvic RT were classified into the bladder tumor (BT) group. The frequency of TERT promoter mutations was 35.7% and 63.6% inthe RA-BT and BT groups, respectively (p = 0.112). Among the other characteristic mutations, FGFR3 and TP53 were frequently observed in both groups (FGFR3: RA-BT vs. BT, 14.3 vs. 42.4%; TP53: RA-BT vs. BT, 50 vs. 33.3%) . Rare mutations in bladder cancer were more frequently observed inthe RA-BT group, including ADGRB3 (28.6%), CBL (21.4%), TGM7 (21.4%), and BTK (14.3%). There were significantly more C → T substitutions in the RA-BT group than in the BT group. In our study, the genetic mutations in the RA-BT group had distinct features from those in the BT group.  \nRadiation therapy (RT) can cause secondary carcinogenesis in various organs1 Patients with bladder cancer who have previously undergone pelvic RT for primary cancer, such as prostate cancer, are more likely to present with locally advanced disease than those without a history of RT. RT is a definitive therapy for localized prostate cancer. According to The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) data, approximately 25% of patients with localized prostate cancer receive RT as their primary treatment modality2 Bostrom et al.3 reported that 18 (54%) of 34 patients with bladder cancer with a history of RT for prostate cancer presented with a locally advanced (pT3-4) tumor. Sha et al.4 compared 1,093 patients with radiation-associated-muscle invasive bladder cancer (RA-MIBC) and 58,997 patients with primary (non-radiation associated) MIBC, and found that RA-MIBCs were more likely to be T4 at diagnosis compared to primary MIBC (21.0 vs. 17.3%, p \u003C 0.001) . RT for prostate cancer has been reported to increase the risk of developing bladder cancer5–7. We previously reported that 14 (2.4%) of 583 patients who underwent brachytherapy for prostate cancer developed bladder cancer8. One of the most common genetic mutations in bladder cancer is the TERT promotor mutations (C228T and C250T)9. Mutations in the TERT promotor have recently been implicated in urothelial carcinogenesis, being present in 60–80% of conventional urothelial carcinomas (UC) and its variants10–13. Most bladder cancers are non-muscle invasive bladder cancers (NMIBCs) at initial diagnosis and less than 20% of bladder cancers are MIBC. Low-grade (LG) and high-grade (HG) bladder cancers have distinct genomic features. LG NMIBC is  \n1Department of Urology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osakasayama 589-8511, Japan. 2Department of Genome Biology, Faculty of Medicine, Kindai University, Osakasayama, Japan. 3Department of Urology, Osaka Minami Medical Center, Kawachinagano, Japan. 4Department of Urology, Mimihara General Hospital, Sakai, Japan. 5Department of Urology, Johns Hopkins University Faculty of Medicine, Baltimore, USA.  \n􀀍","cbCaiqpcwWNRvBuz","https://ap.wps.com/l/cbCaiqpcwWNRvBuz","pdf",2005662,11,"English","# Methods\n## Patient samples\n# Results\n## Mutation profiles and comparisons","[{\"question\":\"How were patients grouped in the study?\",\"answer\":\"Fourteen patients who developed primary bladder cancer after brachytherapy formed the radiation-associated bladder tumor (RA-BT) group. Thirty-three patients with primary bladder cancer without prior pelvic RT were classified as the bladder tumor (BT) group.\"},{\"question\":\"What was the reported frequency of TERT promoter mutations in each group?\",\"answer\":\"TERT promoter mutations occurred in 35.7% of the RA-BT group and 63.6% of the BT group (p = 0.112).\"},{\"question\":\"Which mutation patterns distinguished RA-BT from BT?\",\"answer\":\"RA-BT showed more rare bladder cancer mutations (including ADGRB3, CBL, TGM7, and BTK) and significantly more C→T substitutions compared with the BT group.\"}]","Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers | PDF",1790171670,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2519d908f45d7eaf087ebce2e05e0142.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8601fd01a9f0217778b67ddd799f749b.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68c429e026622d8c793f63e48e26be04.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3f36c1bf51770536653c953bcca9e57.webp",980,1287]